Market Research Report

Needle-Free Delivery: Technology And Market 2013-2023
cover Published by Visiongain
Published Product code 233147
Content info 139 Pages
Price

Introduction

Abstract

Needle-free delivery - discover technological and commercial prospects

What does the future hold for the needle-free delivery market? Visiongain's report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for the overall needle-free injection technology market. There is urgent need for needle-free delivery methods, driven by needle/syringe safety concerns and their lack of suitability for mass immunisation programmes. Our study lets you assess sales data for the global needle-free delivery market, its submarkets and leading national markets. You also find that industry's most promising and lucrative segments, helping your research and analyses.

Forecasts and other analyses to help you stay ahead in knowledge

In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. You see qualitative analysis (SWOT analysis), business news, outlooks and developmental trends. You gain 94 tables and figures and 2 interviews with experts in the field.

Is finding commercial details a challenge? With our report you can get ahead in knowledge, benefiting your research, analyses and decisions. Discover areas that will prosper, reducing the risk of your being left behind.

You discover industry dynamics and growth potentials - the following sections show what you find in our new report.

Discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for these submarkets:

  • Jet Injectors market
  • Competing needle-free technology market

The competing needle-free technology market is further segmented into:

  • Novel needle technology (includes microneedles and pen needles)
  • Inhaler technology
  • Patch technology.

With our investigation you gain business information with individual sales predictions and discussions. You find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can gain competitive advantages by understanding the trends, opportunities and challenges facing the needle-free delivery market.

Our work also breaks the main world forecast into leading geographical markets.

What prospects for leading regions and countries?

Developments worldwide will influence the market from 2013, especially the expansion of healthcare in emerging countries. There are many opportunities for companies developing needle-free technologies. See prospects for the industry.

You get individual forecasts to 2023 for nine national markets, finding overall revenues:

  • US
  • Japan
  • Germany, France, UK, Italy and Spain
  • India and China.

Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What issues will affect the needle-free delivery market?

Our report discusses issues and events affecting that industry and market from 2013, looking ahead:

  • Growing demand for minimally invasive delivery methods
  • Mass immunisation programmes
  • Booming global vaccine market
  • Opportunities in the needle-free delivery market.

Also, you find coverage of these aspects:

  • Regulation of needle-free delivery devices
  • Needle-free devices in development
  • Challenges faced by jet injectors and microneedle technology.

See what the future holds. You investigate technological, commercial, economic and political matters, with emphasis on the competitive landscape and business outlooks.

Leading companies and 2017 market value

What will happen next? We predict the overall world market for needle-free delivery devices will reach $2.4bn in 2017, and expand further to 2023.

Our study shows you what technologies, products and organisations hold greatest potential. We explore these leading companies:

  • Antares Pharma
  • Zogenix
  • Bioject Medical Technologies
  • 3M.

From 2013 to 2023, many opportunities will arise. Our work shows you the technological and commercial possibilities, helping you stay ahead.

Seven ways Needle-Free Delivery: Technology and Market 2013-2023 helps

To sum up, our investigation gives you the following knowledge:

  • Revenues to 2023 for the overall world market and 5 submarkets - you discover that industry's prospects
  • Forecasting to 2023 for the US, Japan, Germany, France, UK, Spain, Italy, India and China - you see leading national sales potentials
  • Assessments of 4 leading companies - you find activities, products, capabilities and outlooks
  • Opinions on the sector - you read our industry interviews with experts
  • Understanding of competition and opportunities - you see what affects that industry, learning what shapes its future
  • Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths
  • Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success.

Benefit from our analyses, gaining information found nowhere else

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative and growth is likely.

With our report you are less likely to fall behind in knowledge or miss opportunity. See how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.

Discover technological and commercial prospects from 2013 by ordering now

Visiongain's study is for everyone needing analysis of the industry and market for needle-free delivery technology. You find data, trends and predictions. Please ask for our report now.

About Visiongain

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical, Defence, Energy and Metals industries.Established in 1998, we have built a strong reputation for covering business-critical topics and investigating issues that other information providers will not.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

Table of Contents

1. Executive Summary

  • 1.1. Sector Highlights
  • 1.2. Aim, Scope and Format of This Report
  • 1.3. Chapter Outline
  • 1.4. Research and Analysis Methods
  • 1.5. Glossary of Terms Relating to the Report

2. Introduction to Needle-Free Delivery of Drug/Vaccines

  • 2.1. What is Needle-Free Technology?
    • 2.1.1. History of Needle-Free Injections (NFI)
  • 2.2. Why the Need For Needle-Free Delivery Technology?
    • 2.2.1. Needle Stick Injury
      • 2.2.1.1. Blood-Borne Pathogens and Needle Stick Injury
      • 2.2.1.2. Accidental Needle Stick Injury: A Serious Healthcare Problem
  • 2.3. Clinical Settings Where Needle-Free Delivery Technology Will Be Beneficial
    • 2.3.1. Pain Management
    • 2.3.2. Vaccine Delivery
      • 2.3.2.1. The Global Vaccine Market, 2012-2023
      • 2.3.2.2. Needle-Free Vaccine Delivery
      • 2.3.2.3. Mass Immunisation
    • 2.3.3. Insulin Delivery For Diabetics
    • 2.3.4. Paediatric Injections
    • 2.3.5. Other Uses For Needle-Free Injection Technology
  • 2.4. Advantages and Disadvantages of Needle-Free Injections
  • 2.5. The Needle-Free Delivery Market
    • 2.5.1. Jet Injectors
      • 2.5.1.1. Strengths and Weaknesses of Jet Injectors
    • 2.5.2. Competing Technologies
      • 2.5.2.1. Novel Needle Technology
        • 2.5.2.1.1. Pen Needles
        • 2.5.2.1.2. Microneedles
        • 2.5.2.1.3. Hollow Microneedles
        • 2.5.2.1.4. Solid Coated Microneedles
        • 2.5.2.1.5. Solid Biodegradable Microneedles
        • 2.5.2.1.6. Solid Uncoated Microneedles
        • 2.5.2.1.7. Selection of Microneedles
      • 2.5.2.2. Inhaler Technology
      • 2.5.2.3. Patch Technology
  • 2.6. Regulation of the Needle-Free Delivery Market
    • 2.6.1. The US Regulation System
    • 2.6.2. The European Regulation System
      • 2.6.2.1. Post Marketing Surveillance in the EU

3. The Needle-Free Delivery Technology Market, 2013-2023

  • 3.1. The Needle-Free Delivery Technology Market: Overview
  • 3.2. The Needle-Free Delivery Technology Market by Segment, 2011
    • 3.2.1. The Needle-Free Delivery Technology Market: Breakdown by Segment, 2011
  • 3.3. The Needle-Free Delivery Market Forecast, 2012-2023
  • 3.4. Needle-Free Delivery Technology: Market Trends, 2013-2023
  • 3.5. Drivers and Restraints in the Needle-Free Delivery Market, 2013-2023
    • 3.5.1. Drivers
      • 3.5.1.1. Growing Demand For Minimally Invasive Delivery Methods
      • 3.5.1.2. Patent Expiry Will Increase Competition
      • 3.5.1.3. Booming Global Vaccines Market
      • 3.5.1.4. Growth in Biologics Market
    • 3.5.2. Restraints
      • 3.5.2.1. Expensive Technology with Currently Limited Market Penetration
      • 3.5.2.2. Limited Clinical Data May Restrain the Market
      • 3.5.2.3. Regulatory Bodies May Restrain Market Growth

4. The Jet Injectors Technology Market, 2013-2023

  • 4.1. The Jet Injectors Market: Overview
  • 4.2. The Jet Injectors Market by Segment, 2011
  • 4.3. The Jet Injectors Market Forecast by Leading Segments, 2012-2017
  • 4.4. The Jet Injectors Market Forecast by Leading Segments, 2017-2023
  • 4.5. Leading Devices in the Jet Injectors Market, 2013
    • 4.5.1. Biojector 2000 (Bioject Medical Technologies)
    • 4.5.2. SUMAVEL DosePro (Zogenix)
    • 4.5.3. E-Jet 100 (Eurojet Medical)
    • 4.5.4. STRATIS (Pharmajet)
    • 4.5.5. ZetaJet (Bioject Medical Technologies)
    • 4.5.6. LectraJet (D'Antonio Consultants International)
    • 4.5.7. Med-Jet (Medical International Technologies)
    • 4.5.8. Vision (Antares Pharma)
    • 4.5.9. Glide System (Glide Pharmaceutical Technologies)
    • 4.5.10. AdvantaJet (Activa Brand Products)
    • 4.5.11. J-Tip (National Medical Products)
    • 4.5.12. SQ-Pen (Diabetes Management International)
    • 4.5.13. Vitajet (Bioject Medical Technologies)
    • 4.5.14. Penjet (Penjet Corporation)
  • 4.6. Jet Injectors Development Pipeline, 2013
    • 4.6.1. Zeneo (Crossject Medical Technologies)
    • 4.6.2. Jupiter Jet (Bioject Medical Technologies)
    • 4.6.3. Iject (Bioject Medical Technologies)
    • 4.6.4. Iject R (Bioject Medical Technologies)
    • 4.6.5. Relday (Zogenix)
  • 4.7. Concluding Remarks

5. Competing Needle-Free Technology Market, 2013-2023

  • 5.1. Competing Needle-Free Technologies: Overview
  • 5.2. Competing Needle-Free Technology Market, 2011
  • 5.3. Competing Needle-Free Technologies Market Forecast by Leading Segments, 2012-2017
  • 5.4. Competing Needle-Free Technologies Market Forecast by Leading Segments, 2017-2023
  • 5.5. Novel Needle Technology, 2011
    • 5.5.1. Novel Needle Technology Market Forecast, 2012-2023
    • 5.5.2. Leading Products in the Microneedle Technology Market, 2013
  • 5.6. Inhaler Technology Market, 2011
    • 5.6.1. Inhaler Technology Market Forecast, 2012-2023
    • 5.6.2. Inhalers in the Asthma Market, 2013
    • 5.6.3. Inhalers in the Insulin Market, 2013
    • 5.6.4. Inhalers in the Vaccine Market, 2013
  • 5.7. Patch Technology Market, 2011
    • 5.7.1. Patch Technology Market Forecast, 2012-2023
    • 5.7.2. Drug Patches in the Market, 2013
    • 5.7.3. Patches For Vaccine Delivery, 2013
  • 5.8. Competing Needle-Free Technology Development Pipeline, 2013
    • 5.8.1. Vaccine Delivery Using Micro-Shock Waves (Indian Institute of Science, Bangalore)
    • 5.8.2. Microneedle Patch For the Polio Vaccine (Georgia Tech's School of Chemical and Biomolecular Engineering)
    • 5.8.3. AdminPen (nanoBioSciences)
    • 5.8.4. PKA SoftTouch (PKA SoftTouch Corp)
    • 5.8.5. Nanotechnology Syringes (Gwangju Institute of Science and Technology, South Korea)
    • 5.8.6. Inhalable Measles Vaccine (Johns Hopkins Bloomberg School of Public Health and the University of Colorado)
    • 5.8.7. Nanotechnology Implant (University of California, San Francisco)
    • 5.8.8. DrugMAT (TheraJect)
    • 5.8.9. MicroCor (Corium International)
  • 5.9. Concluding Remarks

6. Leading National Needle-Free Delivery Markets, 2013-2023

  • 6.1. Regional Breakdown of the Needle-Free Delivery Market, 2011
  • 6.2. Needle-Free Delivery Market: Regional Forecast, 2012-2023
  • 6.3. The US Market
  • 6.4. The European Market
    • 6.4.1. The German Market
    • 6.4.2. The French Market
    • 6.4.3. The Italian Market
    • 6.4.4. The Spanish Market
    • 6.4.5. The UK Market
  • 6.5. The Japanese Market
  • 6.6. The Chinese Market
  • 6.7. The Indian Market

7. Leading Companies in the Needle-Free Delivery Market

  • 7.1. Antares Pharma
    • 7.1.1. Sales and Performance Analysis, 2012
    • 7.1.2. Product Sales, 2012
    • 7.1.3. Technology of Antares Pharma
      • 7.1.3.1. Pressure Assisted Injection Devices
      • 7.1.3.2. Transdermal Gel System
    • 7.1.4. Marketed Products, 2013
    • 7.1.5. Pipeline Products, 2013
  • 7.2. Zogenix
    • 7.2.1. Sales and Performance Analysis, 2011
    • 7.2.2. DosePro - Core Technology of Zogenix
    • 7.2.3. Marketed Products, 2013
    • 7.2.4. Pipeline Products, 2013
  • 7.3. Bioject Medical Technologies
    • 7.3.1. Sales and Performance Analysis
    • 7.3.2. Core Technology of Bioject
    • 7.3.3. Marketed Products, 2013
  • 7.4. 3M
    • 7.4.1. Sales and Performance Analysis, 2011
    • 7.4.2. 3M Drug Delivery Systems

8. Qualitative Analysis of the Needle-Free Delivery Market, 2013-2023

  • 8.1. SWOT Analysis of the Needle-Free Delivery Market, 2013-2023
  • 8.2. Strengths
    • 8.2.1. Needle-Free Injections Offer a Less Painful Alternative
    • 8.2.2. No Specialist Training Required For Drug/Vaccine Delivery
    • 8.2.3. Reduction in Transport Costs
  • 8.3. Weaknesses
    • 8.3.1. Current Technology is Very Expensive
    • 8.3.2. The Manufacturing Process is Slow and Inefficient
    • 8.3.3. Many Drugs Need Reformulating Before Use with Needle-Free Injection Technology
  • 8.4. Opportunities
    • 8.4.1. Emerging Economies Offer Significant Growth Opportunities
    • 8.4.2. Mass Immunisation Programmes Across the Globe
    • 8.4.3. DNA and Other Vaccines Offer Opportunity For Growth
  • 8.5. Threats
    • 8.5.1. Traditional Needles and Syringes are Very Cheap to Mass Produce
    • 8.5.2. Limited Clinical Data Threatens to Stifle Innovation and Restrain the Market
    • 8.5.3. Medical Device Excise Tax

9. Expert Opinions

  • 9.1. Interview with John Turanin, Vice President and General Manager, Zogenix
    • 9.1.1. The Needle-Free Injection Technology Market
    • 9.1.2. Impact of Needle-Free Jet Injectors on Drug and Vaccine Delivery
    • 9.1.3. On SUMAVEL DosePro, a Leading Product in the Market
    • 9.1.4. Factors Limiting the Growth of Jet Injectors
  • 9.2. Interview with Dr Faz Chowdhury, Chief Executive Officer of Nemaura Pharma
    • 9.2.1. Challenges Limiting the Growth of Transdermal Delivery
    • 9.2.2. Growth of Microneedle Patch Technology
    • 9.2.3. Thoughts on Other Needle-Free Technologies in the Market

10. Conclusions

  • 10.1. The Needle-Free Delivery Market, 2013-2023
  • 10.2. Gas/Air Powered Jet Injectors Will Drive the Jet Injectors Market
  • 10.3. Strong Pipeline Will Drive the Competing Needle-Free Injection Technology Market
  • 10.4. Concluding Remarks

List of Tables
  • Table 2.1: The Global Vaccine Market Forecast ($bn), 2011-2023
  • Table 2.2: Rationale For Needle-Free Vaccine Delivery
  • Table 2.3: Key Examples of Needle-Free Vaccine Delivery Systems, 2013
  • Table 2.4: Key Examples of Needle-Free Insulin Delivery Systems For Diabetics, 2013
  • Table 2.5: Advantages and Disadvantages of Needle-Free Injections
  • Table 2.6: Classification of Jet Injectors by Method of Propulsion
  • Table 2.7: Strengths and Weaknesses of Jet Injectors
  • Table 2.8: Pen Needle Technology by Needle Length
  • Table 2.9: FDA Guidance on Regulation of Needle-Free Injectors, 2013
  • Table 3.1: The Needle-Free Delivery Market: Sales ($m) and Market Shares (%) by Segment, 2011
  • Table 3.2: The Needle-Free Delivery Market Forecast ($m) by Segment, 2011-2023
  • Table 3.3: Drivers and Restraints in the Needle-Free Delivery Market, 2013-2023
  • Table 3.4: Patent Expiries For Leading Drugs, 2011-2013
  • Table 3.5: The Global Vaccine Market Forecast ($bn), 2011-2023
  • Table 4.1: The Jet Injectors Market: Sales ($m) and Market Shares (%) by Segment, 2011
  • Table 4.2: The Jet Injectors Market Forecast ($m), 2011-2017
  • Table 4.3: The Jet Injector Market Forecast ($m), 2017-2023
  • Table 4.4: Leading Devices in the Jet Injectors Market, 2013
  • Table 4.5: The Jet Injectors Development Pipeline, 2013
  • Table 4.6: Crossject: Zeneo Development Pipeline, 2013
  • Table 5.1: Competing Needle-Free Technology Market: Sales ($m) and Market Shares (%) by Segment, 2011
  • Table 5.2: Competing Needle-Free Technology Market Forecast ($m) by Segment, 2011-2017
  • Table 5.3: Competing Needle-Free Technology Market Forecast ($m) by Segment, 2017-2023
  • Table 5.4: Novel Needle Technology Market Forecast ($m), 2011-2023
  • Table 5.5: Leading products in the Novel Needle Technology Market, 2013
  • Table 5.6: Inhaler Technology Market Forecast ($m), 2011-2023
  • Table 5.7: Leading Inhalers in the Asthma Market, 2013
  • Table 5.8: Insulin Inhalers Previously Developed and Availability in 2013
  • Table 5.9: Vaccine Inhalers Currently Under Development, 2013
  • Table 5.10: Patch Technology Market Forecast ($m), 2011-2023
  • Table 5.11: Drug Patches in the Market, 2013
  • Table 5.12: Competing Needle-Free Technology Development Pipeline, 2013
  • Table 6.1: Leading National Needle-Free Delivery Markets: Sales ($m) and Market Shares (%), 2011
  • Table 6.2: Needle-Free Delivery Market Forecast ($m) by Leading National Markets, 2011-2017
  • Table 6.3: Needle-Free Delivery Market Forecast ($m) by Leading National Markets, 2017-2023
  • Table 6.4: The Leading European Needle-Free Delivery National Markets: Sales ($m) and Market Shares (%), 2011
  • Table 6.5: The European Needle-Free Delivery Market Forecast ($m) by Leading Countries, 2011-2017
  • Table 6.6: The European Needle-Free Delivery Market Forecast ($m) by Leading Countries, 2017-2023
  • Table 7.1: Antares Pharma: Revenue ($m) and Revenue Shares (%) by Business, 2012
  • Table 7.2: Antares Pharma: Revenue ($m) and Revenue Shares (%), by Product Type, 2012
  • Table 7.3: Antares Pharma: Products Under Development, 2013
  • Table 7.4: Zogenix: Revenue ($m) and Revenue Shares (%), by Business, 2011
  • Table 7.5: Bioject: Revenue ($m) and Revenue Shares (%), by Product Line, 2011
  • Table 7.6: 3M: Net Sales ($bn) and Net Sales Shares (%) by Business Segments, 2011
  • Table 8.1: SWOT Analysis of the Needle-Free Delivery Market, 2013-2023
  • Table 8.2: Average Price For Needle-Free Drug/Vaccine Delivery Technology, 2013
  • Table 10.1: Leading Segments of the Needle-Free Delivery Market ($m), 2011, 2013, 2017 & 2023

List of Figures
  • Figure 2.1: The Global Vaccine Market Forecast ($bn), 2011-2023
  • Figure 3.1: The Needle-Free Delivery Market: Sales ($m) by Segment, 2011
  • Figure 3.2: The Needle-Free Delivery Market: Market Shares (%) by Segment, 2011
  • Figure 3.3: The Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 3.4: The Needle-Free Delivery Market Forecast ($m) by Segment, 2011-2023
  • Figure 3.5: The Global Vaccine Market Forecast ($bn), 2011-2023
  • Figure 4.1: The Jet Injectors Market: Sales ($m) by Segment, 2011
  • Figure 4.2: The Jet Injectors Market: Market Shares (%) by Segment, 2011
  • Figure 4.3: The Jet Injectors Market Forecast ($m), 2011-2017
  • Figure 4.4: The Jet Injectors Market Forecast ($m) by Segment, 2011-2017
  • Figure 4.5: The Jet Injectors Market Forecast ($m), 2017-2023
  • Figure 4.6: The Jet Injectors Market Forecast ($m) by Segment, 2017-2023
  • Figure 5.1: Competing Needle-Free Technology Market: Sales ($m) by Segment, 2011
  • Figure 5.2: Competing Needle-Free Technology Market: Market Shares (%) by Segment, 2011
  • Figure 5.3: Competing Needle-Free Technology Market Forecast ($m), 2011-2017
  • Figure 5.4: Competing Needle-Free Technology Market Forecast ($m) by Segment, 2011-2017
  • Figure 5.5: Competing Needle-Free Technology Market Forecast ($m), 2017-2023
  • Figure 5.6: Competing Needle-Free Technology Market Forecast ($m) by Segment, 2017-2023
  • Figure 5.7: Novel Needle Technology Market Forecast ($m), 2011-2023
  • Figure 5.8: Inhaler Technology Market Forecast ($m), 2011-2023
  • Figure 5.9: Patch Technology Market Forecast ($m), 2011-2023
  • Figure 6.1: Needle-Free Delivery Market: Sales ($m) in Leading National Markets, 2011
  • Figure 6.2: Needle-Free Delivery Market: Market Shares (%) in Leading National Markets, 2011
  • Figure 6.3: US Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.4: The European Needle-Free Delivery Markets: Sales ($m) in Leading National Markets, 2011
  • Figure 6.5: The European Needle-Free Delivery Markets: Market Shares (%) in Leading National Markets, 2011
  • Figure 6.6: The European Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.7: The German Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.8: The French Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.9: The Italian Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.10: The Spanish Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.11: The UK Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.12: The Japanese Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.13: The Chinese Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 6.14: The Indian Needle-Free Delivery Market Forecast ($m), 2011-2023
  • Figure 7.1: Antares Pharma: Revenue ($m) by Business, 2012
  • Figure 7.2: Antares Pharma: Revenue Shares (%) by Business, 2012
  • Figure 7.3: Antares Pharma: Revenue ($m) by Product Type, 2011
  • Figure 7.4: Antares Pharma: Revenue Shares (%) by Product Type, 2011
  • Figure 7.5: Zogenix: Revenue ($m) by Business, 2011
  • Figure 7.6: Zogenix: Revenue Shares (%) by Business, 2011
  • Figure 7.7: Bioject: Revenue ($m) by Product Line, 2011
  • Figure 7.8: Bioject: Revenue Shares (%) by Product Line, 2011
  • Figure 7.9: 3M: Net Sales ($bn) by Business Segments, 2011
  • Figure 8.1: The Transport Process For a Vaccine
  • Figure 10.1: Global Needle-Free Delivery Market Sales ($m) in 2011, 2013, 2017 & 2023
  • Figure 10.2: Global Needle-Free Delivery Market Sales ($m) by Segments in 2011, 2013, 2017 & 2023

Companies Listed

  • 3M
  • Actavis
  • Activa Brand Products
  • Acushot
  • Alkermes
  • Altea Development Corporation
  • Alza
  • Anesiva
  • Antares Pharma
  • Astellas Pharma
  • Astra Zeneca
  • Australian Institute for Bioengineering and Nanotechnology
  • Becton Dickinson
  • Berlex Labs
  • Bespak
  • Bioject Medical Technologies
  • Boehringer Ingelheim
  • Cambridge Consultants
  • Center for Devices and Radiological Health (CDRH)
  • Corium International
  • Crossject Medical Technologies
  • CSL Behring
  • CSL Biotherapies
  • D'Antonio Consultants International
  • Daewoong Pharmaceuticals
  • Debiotech
  • Diabetes Management International
  • Durect
  • Echo Therapeutics
  • Elan Corporation
  • Eli Lily &Co
  • Eloquest Healthcare
  • EMD Serono
  • Emory University
  • Eurojet Medical
  • Ferndale Pharma Group
  • Ferring Pharmaceuticals
  • Food and Drug Administration (FDA) US
  • Generex
  • Georgia Tech's School of Chemical and Biomolecular Engineering
  • GlaxoSmithKline (GSK)
  • Glide Pharmaceutical Technologies
  • Gwangju Institute of Science and Technology
  • Harvard University
  • Indian Institute of Science, Bangalore
  • Intercell
  • Janssen Pharmaceuticals
  • JCR Pharmaceuticals
  • John Hopkins Bloomberg School of Public Health
  • Key Pharmaceuticals
  • Lederle Labs
  • Leiden University
  • LigoCyte Pharmaceuticals
  • Mannkind
  • Medical International Technologies
  • MedImmune
  • Merck &Co
  • NanoBiosciences
  • Nanopass Technologies
  • National Health Service (NHS)
  • National Institute of Health (NIH)
  • National Medical Products
  • Nektar Therapeutics
  • Nemaura Pharma
  • Novartis
  • Novo Nordisk
  • NuPathe
  • Nycomed
  • Ortho-McNiel
  • Owen Mumford
  • Parke-Davis
  • PenJet Corporation
  • Pfizer
  • Pharmacia and Upjohn Company
  • Pharmajet
  • PKA SoftTouch Corp
  • PowderJect Pharmaceuticals
  • Procter and Gamble
  • Sanofi
  • Sanofi-Pasteur
  • Schering
  • Schwarz Pharma
  • Serum Institute of India
  • Shreya Life Sciences
  • Stat Medical Devices
  • State Food and Drug Administration (SFDA) China
  • Teva Pharmaceuticals
  • TheraJect
  • Theratechnologies
  • Trinity Chiesi
  • UCB
  • University Erlangen-Nurnberg
  • University of California
  • University of Colorado
  • University of Queensland
  • Watson Pharmaceuticals
  • World Health Organization (WHO)
  • Zogenix
  • Zosano Pharma
  • Zydus Cadila

Needle-Free Delivery: Technology And Market 2013-2023 published by Visiongain in April 19, 2013. This report consists of 139 Pages and the price starts from US $ 2738.

The contents of this page may be different from the latest version. Please contact us for details.
Back to Top